{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:56:03Z","timestamp":1785581763161,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10741-020-10065-7","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T11:04:29Z","timestamp":1609931069000},"page":"947-952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Beneficial effects on kidney during treatment with sodium-glucose cotransporter 2 inhibitors: proposed role of ketone utilization"],"prefix":"10.1007","volume":"26","author":[{"given":"Yoshiyuki","family":"Hattori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"10065_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1203\/00006450-199710000-00013","volume":"42","author":"T Fukao","year":"1997","unstructured":"Fukao T, Song XQ, Mitchell GA et al (1997) Enzymes of ketone body utilization in human tissues: protein and messenger RNA levels of succinyl-coenzyme A (CoA):3-ketoacid CoA transferase and mitochondrial and cytosolic acetoacetyl-CoA thiolases. Pediatr Res 42:498\u2013502","journal-title":"Pediatr Res"},{"key":"10065_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10741-020-09921-3","volume":"25","author":"Y Hattori","year":"2020","unstructured":"Hattori Y (2020) Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization. Heart Fail Rev 25:403\u2013408","journal-title":"Heart Fail Rev"},{"key":"10065_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39:1108\u20131114","journal-title":"Diabetes Care"},{"key":"10065_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A Unifying Hypothesis Diabetes Care 39:1115\u20131122","journal-title":"A Unifying Hypothesis Diabetes Care"},{"key":"10065_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31\u201339","journal-title":"Lancet"},{"key":"10065_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"10065_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrneph.2012.19","volume":"8","author":"I Helal","year":"2012","unstructured":"Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW (2012) Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 8:293\u2013300","journal-title":"Nat Rev Nephrol"},{"key":"10065_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587\u2013597","journal-title":"Circulation"},{"key":"10065_CR9","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S2213-8587(16)30237-6","volume":"4","author":"RE Gilbert","year":"2016","unstructured":"Gilbert RE (2016) SGLT2 inhibitors: beta blockers for the kidney? Lancet Diabetes Endocrinol 4:814","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10065_CR10","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y (2016) Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8:844\u2013847","journal-title":"J Clin Med Res"},{"key":"10065_CR11","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309:F227\u2013F234","journal-title":"Am J Physiol Renal Physiol"},{"key":"10065_CR12","doi-asserted-by":"crossref","unstructured":"Nespoux J,\u00a0Vallon V (2018) SGLT2 inhibition and kidney protection. Clin Sci (Lond). 132:1329\u20131339","DOI":"10.1042\/CS20171298"},{"key":"10065_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","volume":"133","author":"KC Bedi Jr","year":"2016","unstructured":"Bedi KC Jr, Snyder NW, Brandimarto J et al (2016) Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133:706\u2013716","journal-title":"Circulation"},{"key":"10065_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.23876\/j.krcp.19.063","volume":"38","author":"T Honda","year":"2019","unstructured":"Honda T, Hirakawa Y, Nangaku M (2019) The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract 38:414\u2013426","journal-title":"Kidney Res Clin Pract"},{"key":"10065_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1089\/ars.2016.6664","volume":"25","author":"JC Jha","year":"2016","unstructured":"Jha JC, Banal C, Chow BS et al (2016) Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal 25:657\u2013684","journal-title":"Antioxid Redox Signal"},{"key":"10065_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1755-5922.2010.00218.x","volume":"30","author":"AA Elmarakby","year":"2012","unstructured":"Elmarakby AA, Sullivan JC (2012) Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30:49\u201359","journal-title":"Cardiovasc Ther"},{"key":"10065_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu T, Hirschey MD, Newman J et al (2013) Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339:211\u2013214","journal-title":"Science"},{"key":"10065_CR18","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.3390\/ijms19092630","volume":"19","author":"MJ Hadden","year":"2018","unstructured":"Hadden MJ, Advani A (2018) Histone deacetylase inhibitors and diabetic kidney disease. Int J Mol Sci 19:2630","journal-title":"Int J Mol Sci"},{"key":"10065_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-16-0322","volume":"232","author":"W Dong","year":"2017","unstructured":"Dong W, Jia Y, Liu X et al (2017) Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC. J Endocrinol 232:71\u201383","journal-title":"J Endocrinol"},{"key":"10065_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada T, Muruve DA (2019) The role of inflammasomes in kidney disease. Nat Rev Nephrol 15:501\u2013520","journal-title":"Nat Rev Nephrol"},{"key":"10065_CR21","doi-asserted-by":"crossref","unstructured":"Hutton HL,\u00a0Ooi JD,\u00a0Holdsworth SR et al (2016) Nephrology (Carlton). The NLRP3 Inflammasome in Kidney Disease and Autoimmunity. 21:736\u2013744","DOI":"10.1111\/nep.12785"},{"key":"10065_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW et al (2015) The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 21:263\u2013269","journal-title":"Nat Med"},{"key":"10065_CR23","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517\u20131526","journal-title":"N Engl J Med"},{"key":"10065_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119\u20131131","journal-title":"N Engl J Med"},{"issue":"5","key":"10065_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.kint.2018.11.034","volume":"95","author":"T Tajima","year":"2019","unstructured":"Tajima T, Yoshifuji A, Matsui A, Itoh T, Uchiyama K, Kanda T, Tokuyama H, Wakino S, Itoh H (2019) Kidney Int 95(5):1120\u20131137","journal-title":"Kidney Int"},{"key":"10065_CR26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-10065-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10065-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T05:27:49Z","timestamp":1621920469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-10065-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10065"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10065-7","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"8 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}